DAX24.122 +0,4%ESt505.454 ±0,0%Top 10 Crypto14,98 +3,3%Dow42.385 -0,7%Nas19.236 +0,5%Bitcoin96.601 +2,2%Euro1,1341 +0,5%Öl65,03 -0,9%Gold3.307 +0,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 RENK RENK73 NVIDIA 918422 D-Wave Quantum A3DSV9 HENSOLDT HAG000 BYD A0M4W9 Tesla A1CX3T Lufthansa 823212 Infineon 623100 Siemens Energy ENER6Y Deutsche Telekom 555750 Deutsche Bank 514000 Allianz 840400 Bayer BAY001 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
24.100-Punkte-Marke geknackt: DAX schließt mit neuem Rekord -- DeuBa bewertet wieder Intel -- Xpeng, Wolfspeed, Infineon, NVIDIA, Rheinmetall, RENK, HENSOLDT, Bitcoin im Fokus
Top News
Bitcoinkurs erreicht neues Allzeithoch Bitcoinkurs erreicht neues Allzeithoch
DAX hat Jahresendziel bei 24.000 Punkten schon deutlich übertroffen - wie realistisch sind Expertenprognosen? DAX hat Jahresendziel bei 24.000 Punkten schon deutlich übertroffen - wie realistisch sind Expertenprognosen?
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Ipsen Aktie

NeuKaufenVerkaufen
Ipsen Aktien-Sparplan
102,10 EUR -1,70 EUR -1,64 %
STU
102,70 EUR -1,60 EUR -1,53 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.8,46 Mrd. EUR

KGV26,49Div. Rendite1,26%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0ESMG

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINFR0010259150

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIPSEF

Ipsen Aktien News

DatumMeistgelesen
GlobeNewswireIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024
GlobeNewswireIpsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireHalf-year statement of IPSEN liquidity agreement - 2024 06 30
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024
GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
BenzingaFDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
GlobeNewswireIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
GlobeNewswireIpsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   
GlobeNewswireIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    
GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan
GlobeNewswireIpsen announces the launch of an employee shareholding plan
GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024
GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024
GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America
GlobeNewswireIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
GlobeNewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
GlobeNewswireIpsen publishes its 2023 Universal Registration Document
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
GlobeNewswireIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen S.A. publishes its 2023 Consolidated Financial Statements
GlobeNewswireIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
GlobeNewswireBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireLatest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024
GlobeNewswireIpsen – Half year statement – 2023 12 31
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital
Wer­bung

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.